VALSARTAN AND HYDROCHLOROTHIAZIDE Drug Patent Profile
✉ Email this page to a colleague
When do Valsartan And Hydrochlorothiazide patents expire, and what generic alternatives are available?
Valsartan And Hydrochlorothiazide is a drug marketed by Alembic, Amneal Pharms, Apotex Inc, Aurobindo Pharma Ltd, Lupin Ltd, Macleods Pharms Ltd, Mylan Pharms Inc, Prinston Inc, Watson Labs Teva, and Zydus Lifesciences. and is included in ten NDAs.
The generic ingredient in VALSARTAN AND HYDROCHLOROTHIAZIDE is hydrochlorothiazide; valsartan. There are thirty-two drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; valsartan profile page.
Summary for VALSARTAN AND HYDROCHLOROTHIAZIDE
| US Patents: | 0 |
| Applicants: | 10 |
| NDAs: | 10 |
| Finished Product Suppliers / Packagers: | 20 |
| Raw Ingredient (Bulk) Api Vendors: | 3 |
| Clinical Trials: | 43 |
| Patent Applications: | 219 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in VALSARTAN AND HYDROCHLOROTHIAZIDE? | VALSARTAN AND HYDROCHLOROTHIAZIDE excipients list |
| DailyMed Link: | VALSARTAN AND HYDROCHLOROTHIAZIDE at DailyMed |
Recent Clinical Trials for VALSARTAN AND HYDROCHLOROTHIAZIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Farma de Colombia SA | Phase 3 |
| Damanhour University | N/A |
| University of Birmingham | Phase 3 |
Pharmacology for VALSARTAN AND HYDROCHLOROTHIAZIDE
| Drug Class | Angiotensin 2 Receptor Blocker Thiazide Diuretic |
| Mechanism of Action | Angiotensin 2 Receptor Antagonists |
| Physiological Effect | Increased Diuresis |
Anatomical Therapeutic Chemical (ATC) Classes for VALSARTAN AND HYDROCHLOROTHIAZIDE
US Patents and Regulatory Information for VALSARTAN AND HYDROCHLOROTHIAZIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Watson Labs Teva | VALSARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; valsartan | TABLET;ORAL | 091519-001 | Mar 21, 2013 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Mylan Pharms Inc | VALSARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; valsartan | TABLET;ORAL | 078020-002 | Sep 21, 2012 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Zydus Lifesciences | VALSARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; valsartan | TABLET;ORAL | 203000-004 | Mar 15, 2019 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Watson Labs Teva | VALSARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; valsartan | TABLET;ORAL | 091519-005 | Mar 21, 2013 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
